Signatera ctDNA Subsequent Test in Lahore at Chughtai Lab

Signatera Subsequent Test circulating Tumor DNA at Chughtai Lab

The Signatera Subsequent Test for circulating tumor DNA (ctDNA) represents a paradigm shift in oncology diagnostics, offering a highly personalized, molecular-level approach to cancer surveillance and treatment monitoring. Available through Chughtai Lab, Pakistan’s premier diagnostic network headquartered in Lahore, this advanced liquid biopsy test is custom-designed for each patient. Unlike generic liquid biopsies that scan for common cancer-associated mutations, Signatera is a “tumor-informed” assay. It utilizes genomic data from the patient’s own primary tumor tissue to identify a unique signature of 16 clonal somatic mutations. The subsequent blood tests are then custom-manufactured to detect these specific mutations in cell-free DNA circulating in the bloodstream.

This ultra-sensitive molecular technology is primarily used to detect molecular residual disease (MRD) after surgical resection or definitive therapy. By identifying minute quantities of tumor DNA shedding into the blood long before clinical or radiological recurrence can be detected by traditional imaging like CT, MRI, or PET scans, Signatera empowers oncologists to make highly informed, proactive treatment decisions. The clinical utility of this test spans multiple solid tumors, including colorectal, breast, lung, and urinary bladder cancers. By monitoring ctDNA levels longitudinally, physicians can evaluate the effectiveness of adjuvant therapies, assess real-time response to immunotherapies, and detect molecular relapse up to two years earlier than standard imaging modalities.

At Chughtai Lab, we combine our extensive diagnostic infrastructure across Pakistan with state-of-the-art molecular pathology protocols to facilitate this highly complex test. By analyzing the patient’s blood samples with next-generation sequencing (NGS) and multiplex polymerase chain reaction (PCR) technologies, the Signatera Subsequent Test delivers unparalleled specificity (greater than 99.8%) and high sensitivity, providing patients and oncologists with reliable, actionable insights for personalized cancer management.

Clinical Procedure: What to Expect

Patient Preparation

Because the Signatera Subsequent Test is a specialized blood-based liquid biopsy, the preparation required is minimal compared to invasive tissue biopsies or complex imaging studies. Patients should observe the following guidelines to ensure an optimal sample collection:

• No Fasting Required: Patients do not need to fast before the blood draw. You may eat and drink normally prior to your appointment.
• Hydration: It is highly recommended to drink plenty of water before the procedure. Proper hydration dilates veins, making the venipuncture process smoother and more comfortable.
• Medication Review: Continue taking all prescribed medications as directed by your physician. There are no general medication restrictions, but you should inform the phlebotomist if you are taking blood thinners.
• Documentation: Ensure you bring your previous Signatera baseline reports, clinical history, and your oncologist’s prescription to Chughtai Lab.
• Scheduling: Coordinate the blood draw timing with your oncologist’s recommended monitoring schedule, which is typically aligned with chemotherapy cycles or routine follow-up intervals.

During the Procedure

The collection process for the Signatera Subsequent Test is straightforward, safe, and completed within a few minutes at a Chughtai Lab diagnostic center or through our home sample collection service:

• Patient Positioning: You will be comfortably seated in a phlebotomy chair. The phlebotomist will ask you to extend your arm and will locate a suitable vein, typically in the antecubital fossa (inner elbow).
• Sanitization: The skin over the selected vein is thoroughly cleansed with an antiseptic swab to prevent any contamination.
• Sample Collection: A sterile, single-use needle is inserted into the vein. The phlebotomist will draw blood into two specialized cell-free DNA (cfDNA) preservation tubes (often Streck tubes). These tubes contain specific preservatives that prevent healthy white blood cells from lysing and diluting the tumor DNA.
• Volume and Duration: Approximately 10 to 20 milliliters of blood are collected. The entire venipuncture process takes less than five minutes.
• Post-Collection Care: After removing the needle, gentle pressure is applied to the puncture site with a sterile cotton ball, followed by the application of a small bandage. You can resume your daily activities immediately.
• Sample Transport: The collected blood samples are carefully packaged under strict temperature-controlled conditions and dispatched to the specialized molecular laboratory for next-generation sequencing analysis.

When is a Signatera Subsequent Test Performed?

Colorectal Cancer Post-Surgical Surveillance

In patients diagnosed with colorectal cancer, the Signatera Subsequent Test is performed at regular intervals following surgical resection. The primary clinical objective is to detect molecular residual disease (MRD). If ctDNA is detected in the blood post-surgery, it indicates that microscopic tumor cells remain in the body, placing the patient at an extremely high risk of recurrence. This early detection allows oncologists to initiate adjuvant chemotherapy promptly, targeting the microscopic disease before it manifests as macroscopic tumors on radiological scans.

Breast Cancer Recurrence Monitoring

For breast cancer patients, particularly those with high-risk early-stage disease, the Signatera Subsequent Test is used as a longitudinal monitoring tool after the completion of primary therapies. Because breast cancer can recur years after initial treatment, tracking ctDNA levels over time provides a highly sensitive early warning system. Detecting a rise in patient-specific tumor mutations in the blood allows for early intervention, potentially modifying endocrine therapy or initiating targeted therapies to prevent clinical relapse.

Non-Small Cell Lung Cancer (NSCLC) Follow-Up

In non-small cell lung cancer, where recurrence rates remain high even after successful surgical resection or chemoradiation, the Signatera Subsequent Test serves as a critical surveillance tool. Physicians request this test during the post-treatment follow-up phase to monitor for molecular relapse. Because lung cancer recurrence can be aggressive, detecting ctDNA clearance or re-emergence helps clinicians evaluate whether the patient requires additional systemic therapy or a change in their surveillance imaging frequency.

Monitoring Immunotherapy Response

The Signatera Subsequent Test is increasingly utilized in patients undergoing immunotherapy (such as immune checkpoint inhibitors) for advanced solid tumors. Traditional imaging can sometimes show a temporary increase in tumor size, a phenomenon known as pseudoprogression, which is difficult to differentiate from true disease progression. By measuring ctDNA levels, oncologists can determine if the tumor DNA is decreasing (indicating a positive response to immunotherapy) or increasing (indicating treatment failure), enabling timely therapeutic adjustments.

Detection of Molecular Residual Disease (MRD)

The detection of molecular residual disease is the cornerstone of personalized oncology. The Signatera Subsequent Test is performed after any definitive cancer treatment—such as surgery, chemotherapy, or radiation therapy—to confirm whether the body is entirely free of tumor DNA. A negative result provides significant clinical reassurance of a low risk of recurrence, while a positive result alerts the medical team to the presence of active, microscopic disease that requires close monitoring or immediate therapeutic intervention.

What Does a Signatera Subsequent Test Detect?

The Signatera Subsequent Test is designed to detect and quantify highly specific molecular parameters associated with a patient’s unique tumor profile. The key clinical and molecular findings detected by this test include:

• Presence of Patient-Specific Somatic Mutations: Detects the presence of any of the 16 personalized clonal mutations identified during the baseline tissue analysis.
• Circulating Tumor DNA (ctDNA) Status: Reports the qualitative result as either “Detected” (positive) or “Not Detected” (negative).
• ctDNA Concentration: Quantifies the amount of tumor DNA in the bloodstream, measured in Mean Tumor Molecules per milliliter (MTM/mL).
• Molecular Residual Disease (MRD): Identifies the presence of microscopic residual tumor cells after definitive surgical resection.
• Longitudinal ctDNA Trends: Tracks whether ctDNA levels are rising, falling, or remaining stable over multiple testing intervals.
• Early Molecular Relapse: Detects tumor recurrence at the molecular level, often months or years before it becomes visible on CT, MRI, or PET scans.
• Therapeutic Response: Evaluates the clearance of ctDNA as an indicator of successful response to adjuvant chemotherapy or radiation.
• Immunotherapy Efficacy: Assesses real-time changes in ctDNA levels to differentiate between true tumor progression and immunotherapy-induced pseudoprogression.
• Minimal Residual Disease Clearance: Confirms the absence of detectable tumor DNA, indicating a high likelihood of surgical cure.
• Clonal Evolution Indicators: Monitors the persistence of primary clonal mutations, helping clinicians understand the genomic stability of the disease.
• Risk of Distant Metastasis: A persistently positive ctDNA status correlates strongly with an increased risk of distant metastatic recurrence.
• Treatment Resistance: A rising trend in MTM/mL despite active therapy suggests the development of treatment resistance.
• Post-Treatment Baseline: Establishes a new molecular baseline after the completion of a specific line of therapy.
• Shedding Dynamics: Analyzes the biological shedding patterns of the specific tumor type into the systemic circulation.
• Cell-Free DNA (cfDNA) Background: Measures the total background cell-free DNA, which includes DNA from normal cells, to ensure sample quality.
• Assay Sensitivity Thresholds: Verifies that the sample met the stringent quality control metrics required to detect low-abundance mutations.
• Targeted Mutation Persistence: Identifies which specific mutations among the personalized panel remain detectable over time.
• Prognostic Stratification: Provides molecular data that stratifies patients into high-risk or low-risk categories for disease recurrence.
• Adjuvant Therapy Benefit: Helps determine if a patient is likely to benefit from additional cycles of chemotherapy based on ctDNA clearance.
• Molecular Remission: Documents sustained periods of undetectable ctDNA, supporting long-term surveillance strategies.

Turnaround Time and Report Access at Chughtai Lab

The Signatera Subsequent Test is a highly sophisticated molecular assay that involves personalized next-generation sequencing. Because each test is custom-tailored to the patient’s unique genetic tumor profile, the processing time is longer than standard laboratory investigations. Typically, the turnaround time for the Signatera Subsequent Test at Chughtai Lab is approximately 2 to 3 weeks from the date of sample collection. This period is required for specialized transport, DNA extraction, high-throughput sequencing, and rigorous bioinformatic analysis to ensure absolute accuracy.

Chughtai Lab provides seamless and convenient access to diagnostic reports. Once the analysis is complete and verified by our consultant molecular pathologists, patients and their referring oncologists are notified immediately via SMS. Reports can be accessed and downloaded online through the secure Chughtai Lab website portal or via the Chughtai Lab Mobile App. Physical copies of the reports can also be collected from any of our main diagnostic centers in Lahore and other major cities across Pakistan. Our dedicated customer care team is available to assist patients in retrieving their results and coordinating with their healthcare providers.

Signatera Subsequent Test Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
ctDNA Status	Not Detected (Negative)	Detected (Positive)
ctDNA Concentration (MTM/mL)	0.00 MTM/mL (No detectable tumor molecules)	Elevated levels (e.g., >0.01 MTM/mL up to thousands of MTM/mL)
Molecular Residual Disease (MRD)	No evidence of MRD; high probability of complete surgical resection	Presence of MRD; indicative of persistent microscopic disease
Longitudinal ctDNA Trend	Sustained undetectable levels over consecutive tests	Rising trend in MTM/mL over sequential testing intervals
Response to Adjuvant Therapy	Rapid clearance of ctDNA to undetectable levels post-treatment	Persistent or rising ctDNA levels despite active chemotherapy
Immunotherapy Monitoring	Significant decrease or clearance of ctDNA within weeks of initiation	Continuous rise in ctDNA, confirming true disease progression
Risk of Recurrence	Low clinical risk of short-term recurrence	High clinical risk of radiological and clinical recurrence
Sample Quality Control	Adequate cell-free DNA (cfDNA) yield with no cellular contamination	Inadequate cfDNA yield or high genomic DNA contamination (requires redraw)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Signatera Subsequent Test?

• Pioneering Molecular Diagnostics: Chughtai Lab is at the forefront of introducing advanced genomic and personalized medicine solutions in Pakistan.
• ISO 15189 Certified Laboratories: Our main testing facilities adhere to international quality standards, ensuring the highest level of accuracy and reliability.
• Convenient Home Sample Collection: Patients can have their blood drawn in the comfort of their homes by our highly trained, professional phlebotomists.
• Nationwide Network: With a presence in Lahore, Karachi, Islamabad, and dozens of other cities, we ensure easy access to specialized testing.
• Expert Pathologist Oversight: Our molecular pathology department is led by highly qualified consultant pathologists with extensive experience in genomic diagnostics.
• Secure Digital Report Access: Easily view, download, and share your highly confidential molecular reports via our user-friendly mobile app and online portal.
• Cold-Chain Logistics: We utilize specialized, temperature-controlled transport systems to maintain sample integrity from collection to analysis.
• Patient-Centric Support: Our dedicated customer support team is trained to assist cancer patients and their families through every step of the testing process.